, Tracking Stock Market Picks
Enter Symbol:
Advaxis, Inc. (ADXS) [hlAlert]

down 6.02 %

Advaxis, Inc. (ADXS) rated Overweight with price target $40 by Barclays

Posted on: Tuesday,  Sep 22, 2015  1:25 PM ET by Barclays

Barclays rated Overweight Advaxis, Inc. (NASDAQ: ADXS) on 09/22/2015, when the stock price was $15.93. Since
then, Advaxis, Inc. has lost 6.03% as of 01/21/2016's recent price of $14.97.
If you would have followed this Barclays's recommendation on ADXS, you would have lost 6.02% of your investment in 121 days.

Advaxis, Inc. is a development-stage biotechnology company with the focus on developing cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania (Penn), which secretes a protein sequence containing a tumor-specific antigen. This technology involves the creation of genetically engineered Listeria that stimulates the innate immune system and induces an antigen-specific immune response involving both arms of the adaptive immune system. The Company?s products in development are ADXS11-001, ADXS31-142 and ADXS31-164. The Company uses genetically engineered and attenuated Listeria monocytogenes as a therapeutic agent. The Company?s agent ADX11-001, uses a human papilloma virus (HPV) derived antigen that is present in cervical cancers.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/22/2015 1:25 PM Buy
15.93 40.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy